4.2 Article

Syndrome Disintegration: Exome Sequencing Reveals that Fitzsimmons Syndrome is a Co-Occurrence of Multiple Events

Journal

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
Volume 170, Issue 7, Pages 1820-1825

Publisher

WILEY-BLACKWELL
DOI: 10.1002/ajmg.a.37684

Keywords

syndrome; exome sequencing; Fitzsimmons syndrome; ARSACS; Trichorhinophalangeal syndrome type 1; concomitant mutations

Funding

  1. Genome Canada
  2. Canadian Institutes of Health Research (CIHR)
  3. Ontario Genomics Institute [OGI-049]
  4. Genome Quebec
  5. Genome British Columbia

Ask authors/readers for more resources

In 1987 Fitzsimmons and Guilbert described identical male twins with progressive spastic paraplegia, brachydactyly with cone shaped epiphyses, short stature, dysarthria, and low-normal intelligence. In subsequent years, four other patients, including one set of female identical twins, a single female child, and a single male individual were described with the same features, and the eponym Fitzsimmons syndrome was adopted (OMIM #270710). We performed exome analysis of the patient described in 2009, and one of the original twins from 1987, the only patients available from the literature. No single genetic etiology exists that explains Fitzsimmons syndrome; however, multiple different genetic causes were identified. Specifically, the twins described by Fitzsimmons had heterozygous mutations in the SACS gene, the gene responsible for autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS), as well as a heterozygous mutation in the TRPS1, the gene responsible in Trichorhinophalangeal syndrome type 1 (TRPS1 type 1) which includes brachydactyly as a feature. A TBL1XR1 mutation was identified in the patient described in 2009 as contributing to his cognitive impairment and autistic features with no genetic cause identified for his spasticity or brachydactyly. The findings show that these individuals have multiple different etiologies giving rise to a similar phenotype, and that Fitzsimmons syndrome is in fact not one single syndrome. Over time, we anticipate that continued careful phenotyping with concomitant genome-wide analysis will continue to identify the causes of many rare syndromes, but it will also highlight that previously delineated clinical entities are, in fact, not syndromes at all. (C) 2016 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available